Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: Value of F-18 fluorodeoxyglucose PET

Annals of the Rheumatic Diseases

Volumn 59, Issue 5, 2000, Pages 377-385

  Weiner, S M ^a   Peter, H H ^a   Otte, A ^b   Schumacher, M ^a   Klein, R ^c   Gutfleisch, J ^a   Brink, I ^a   Otto, P ^a   Nitzsche, E U ^a   Moser, E ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS; MALE; NEUROLOGIC DISEASE; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BRAIN DISEASES; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034107307     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.59.5.377     Document Type: Article

References (61)

1. 1 Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98: 32-41.
2. 2 Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955-1977. Semin Arthritis Rheum 1979;8:212-21.
3. 3 How A, Dent PB, Liao SK, Denburg JA. Antineuronal antibodies in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1985;28:789-95.
4. 4 Long AA, Denburg SD, Carbotte RM, Singal DP, Denburg JA. Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus. Ann Rheum Dis 1990;49:249-53
5. 5 Sibley JT, Olszynski WP, Decoteau WP, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992;19:47-52
6. 6 Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991;90:54-62.
7. 7 Bluestein HG. Neurocytotoxic antibodies in serum of patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 1978;75:3965-9.
8. 8 Diederichsen H, Pyndt IC. Antibodies against neurons in a patient with systemic lupus erythematosus, cerebral palsy, and epilepsy. Rrain 1970;93:407-12.
9. 9 Klein R, Richter C, Berg PA. Antibodies against central nervous system tissue (anti-CNS) detected by ELISA and western blotting: marker antibodies for neuropsychiatric manifestations in connective tissue diseases. Autoimmunity 1991;10:133-44.
10. 10 Teh L, Isenberg DA. Antiribosomal P protein antibodies in systemic lupus erythematosus. Arthritis Rheum 1994;37: 307-15.
11. 11 Stimmler MM, Coletti PM, Quismorio FP Jr. Magnetic resonance imaging of the brain in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 1993;22:335-19.
12. 12 West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995;99:153-63.
13. 13 Kozora E, West SG, Kotzin BL, Julian L, Porter S, Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1998;41:41-7.
14. 14 Kovacs JA, Urowitz MB, Gladman DD, Zeman R. The use of single photon emission computerized tomography in neuropsychiatric SLE: a pilot study. J Rheumatol 1995;22: 1247-53.
15. 15 Falcini F, De Cristofaro MT, Ermini M, Guarnien M, Massai G, Olmastroni M, et al. Regional cerebral blood flow in juvenile systemic lupus erythematosus: a prospective SPECT study Single photon emission computed tomography. J Rheumatol 1998;25:583-8.
16. 16 Meyer GJ, Schober O, Stoppe G, Wildhagen K, Seidel JW, Hundeshagen H. Cerebral involvement in systemic lupus erythematosus (SLE): comparison of positron emission tomography (PET) with other imaging methods. Psychiatry Res 1989;29:367-8.
17. 17 Stoppe G, Wildhagen K, Seidel JW, Meyer GJ, Schober O, Heintz P, et al. Positron emission tomography in neuropsychiatric lupus erythematosus. Neurology 1990;40:304-8.
18. 18 Otte A, Weiner SM, Peter HH, Mueller-Brand J, Goetze M, Moser E, et al. Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography study. Eur J Nucl Med 1997;24:787-91.
19. 19 Grunwald F, Schomburg A, Badali A, Ruhlmann J, Pavics L, Biersack HJ. 18FDG PET and acetazolamide-enhanced 99mTc-HMPAO SPET in systemic lupus erythematosus. Eur J Nucl Med 1995;22:1073-7.
20. 20 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
21. 21 Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
22. 22 ACR Ad Hoc Committee on Neuropsychiatric Lupus nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608
23. 23 Hamacher K, Goenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8.
24. 24 Huang SC, Carson R, Phelps M, Hoffman E, Schelbert H, Kuhl D. A boundary method for attenuation correction in positron emission tomography. IEEE Trans Nucl Sci 1981; 22:627-37.
25. 25 Rother E, Lang B, Coldewey R, Hartung K, Peter HH. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus. Clin Rheumatol 1993;12:31-5.
26. 20 Kushner MJ, Chawluk J, Fazekas F, Mandell B, Burke A, Jaggi J, et al. Ceerebral blood flow in systemic lupus erythematosus with or without cerebral complications. Neurology 1987;37:1596-8.
27. 27 Awada HH, Mamo HL, Luft AG, Ponsin JC, Kahn MF. Cerebral blood flow in systemic lupus erythematosus with and without central nervous system involvement. J Neurol Neurosurg Psychiatry 1987;50:1597-601.
28. 28 Rubbert A, Marienhagen J, Pirner K, Manger B, Grebmeier J, Engelhardt A, et al. Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum 1993;36:1253-62.
29. 20 Reif A, Miller J, Shaham B, Bernstein B, Szer IS. Childhood central nervous system lupus; longitudinal assessment using single photon emission computed tomography. J Rheumatol 1997;24:2461-5.
30. 30 Emmi I., Bramati M, De Cristofaro MT, Masealchi M, Dal Pozzo G, Marconi GP, et al. MRI and SPECT investigations of the CNS in SLE patients. Clin Exp Rheumatol 1993;11:13-20.
31. 31 Sailer M, Burchert W, Ehrenheim C, Smid HG, Haas J, Wildhagen K, et al. Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol 1997;244:186-93.
32. 32 Chinn RJ, Wilkinson ID, Hall-Craggs MA, Paley MN, Shortall E, Carter S, et al. Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40: 36-46.
33. 33 Kao C-H, Ho Y-J, Lan J-L, Changlai S-P, Liao K-K, Chieng P-U. Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. Arthritis Rheum 1999;42: 61-8.
34. 34 Higashi K, Nishikawa T, Seki H, Oguchi M, Nambu Y, Ueda Y, et al. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. J Nucl Med 1998;39:9-15.
35. 35 Otte A, Ettlin TM, Nitzsche EU, Wachter K, Hoegerle S, Simon GH, et al. PET and SPECT in whiplash syndrome: a new approach to a forgotten brain? J Neurol Neurosurg Psychiatry 1997;63:368-72.
36. 36 Carbotte RM, Denburg SD, Denburg JA, Nahmias C, Garnett ES. Fluctuating cognitive abnormalities and cerebral glucose metabolism in neuropsychiatrie systemic lupus erythematosus. J Neurol Neurosurg Psychiatry 1992;55: 1054-9.
37. 37 Csepany T, Gulyas B, Tron L, Szakall S, Kiss E, Kollar J, et al. Cerebral positron emission tomographic study in systemic lupus erythematosus. Orv Hetil 1997;138:1947-52.
38. 38 Hiraiwa M, Nonaka C, Abe T, Iio M. Positron emission tomography in systemic lupus erythematosus: relation of cerebral vasculitis to PET findings. AJNR Am J Neuroradiol 1983;4:541-3.
39. 39 Otte A, Mueller-Brand J, Fierz L. Brain SPECT findings in late whiplash syndrome. Lancet 1995;345:151-3.
40. 40 Waldemar G, Bruhn P, Kristensen M, Johnsen A, Paulson OB, Lassen NA. Heterogeneity of neocortical cerebral blood flow deficits in dementia of the Alzheimer type: a [99mTc]-d,1-HMPAO SPECT study. J Neurol Neurosurg Psychiatry 1994;57:285-95.
41. 41 Kodama K, Okada S, Hino T, Takabayashi K, Nawata Y, Uchida Y, et al. Single photon emission computed tomography in systemic lupus erythematosus with psychiatric symptoms. J Neurol Neurosurg Psychiatry 1995;58:307-11.
42. 42 Otte A, Weiner SM, Hoegerle S, Wolf R, Juengling FD, Peter HH, et al. Neuropsychiatric systemic lupus erythematosus before and after immunosuppressive treatment: a FDG PET study. Lupus 1998;7:57-9.
43. 43 Hanly JG, Cassell K, Fisk JD. Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum 1997;40:1542-3.
44. 44 Hay EM, Huddy A, Black D, Mbaya P, Tomenson B, Bernstein RM, et al. A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. Ann Rheum Dis 1994;53:298-303.
45. 45 Chawluk JB, Alavi A, Dann R, Hurtig HI, Bais S, Kushner MJ, et al. Positron emission tomography in aging and dementia: effect of cerebral atrophy. J Nucl Med 1987;28: 431-7.
46. 46 Feeney DM, Baron JC. Diaschisis. Stroke 1986;17:817-30.
47. 47 Hanly JG. Single photon emission computed tomography scanning in neuropsychiatric systemic lupus erythematosus. J Rheumatol 1998;25:401-3.
48. 48 Briley DP, Coull BM, Goodnight SH, Jr. Neurological disease associated with antiphospholipid antibodies. Ann Neurol 1989;25:221-7.
49. 49 Levine SR, Welch KM. The spectrum of neurologic disease associated with antiphospholipid antibodies: Lupus anticoagulants and anticardiolipin antibodies. Arch Neurol 1987; 44:876-83.
50. 50 Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus: Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996;39:9-22.
51. 51 van Dam AP. Diagnosis and pathogenesis of CNS lupus. Rheumatol Int 1991;11:1-11.
52. 52 Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988;31:632-41.
53. 53 Abramson SB, Weissmann G. Complement split products and the pathogenesis of SLE. Hosp Prac 1988;23:45-56.
54. 54 Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987;317:265-71.
55. 55 Arnett FC, Reveille JD, Moutsopoulos HM, Georgescu L, Elkon KB. Ribosomal P autoantibodies in systemic lupus erythematosus: Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum 1996;39:1833-9.
56. 56 Teh LS, Bedwell AE, Isenberg DA, Gordon C, Emery P, Charles PJ, et al. Antibodies to protein P in systemic lupus erythematosus. Ann Rheum Dis 1992;51:489-94.
57. 57 Van Dam A, Nossent H, de Jong J, Meilof J, ter Borg E-J, Swaak T, et al. Diagnostic value of antibodies against ribosomal phosphoprotiens: a cross sectional and longitudinal study. J Rheumatol 1991;18:1026-34.
58. 58 Bruyn GAW. Controversies in lupus: nervous system involvement. Ann Rheum Dis 1995; 54: 159-67.
59. 59 Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum 1992; 35:417-22.
60. 60 Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990; 33:644-9.
61. 61 Jüngling FD, Lieb K, Gut O, Bauer J, Moser E, Nitzsche EU. FDG-PET zum Nachweis IFN-alpha assoziierter zerebraler Glukosestoffwechselstörungen. Nuklearmedizin 1999; 38:A21.